ERYP vs. AURA, ALLO, PRME, KOD, RGNX, CMPX, VALN, GLUE, NMRA, and ENGN
Should you be buying ERYTECH Pharma stock or one of its competitors? The main competitors of ERYTECH Pharma include Aura Biosciences (AURA), Allogene Therapeutics (ALLO), Prime Medicine (PRME), Kodiak Sciences (KOD), REGENXBIO (RGNX), Compass Therapeutics (CMPX), Valneva (VALN), Monte Rosa Therapeutics (GLUE), Neumora Therapeutics (NMRA), and enGene (ENGN). These companies are all part of the "biological products, except diagnostic" industry.
ERYTECH Pharma vs.
Aura Biosciences (NASDAQ:AURA) and ERYTECH Pharma (NASDAQ:ERYP) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, media sentiment, community ranking, risk, profitability, valuation and earnings.
96.8% of Aura Biosciences shares are held by institutional investors. Comparatively, 1.1% of ERYTECH Pharma shares are held by institutional investors. 5.4% of Aura Biosciences shares are held by insiders. Comparatively, 1.9% of ERYTECH Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
ERYTECH Pharma received 139 more outperform votes than Aura Biosciences when rated by MarketBeat users. However, 62.16% of users gave Aura Biosciences an outperform vote while only 57.45% of users gave ERYTECH Pharma an outperform vote.
Aura Biosciences presently has a consensus target price of $23.00, indicating a potential upside of 190.04%. Given Aura Biosciences' stronger consensus rating and higher possible upside, research analysts plainly believe Aura Biosciences is more favorable than ERYTECH Pharma.
ERYTECH Pharma has higher revenue and earnings than Aura Biosciences.
In the previous week, Aura Biosciences had 9 more articles in the media than ERYTECH Pharma. MarketBeat recorded 9 mentions for Aura Biosciences and 0 mentions for ERYTECH Pharma. Aura Biosciences' average media sentiment score of 0.43 beat ERYTECH Pharma's score of 0.00 indicating that Aura Biosciences is being referred to more favorably in the media.
ERYTECH Pharma's return on equity of 0.00% beat Aura Biosciences' return on equity.
Aura Biosciences has a beta of 0.3, indicating that its stock price is 70% less volatile than the S&P 500. Comparatively, ERYTECH Pharma has a beta of 2.69, indicating that its stock price is 169% more volatile than the S&P 500.
Summary
Aura Biosciences beats ERYTECH Pharma on 9 of the 15 factors compared between the two stocks.
Get ERYTECH Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for ERYP and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ERYTECH Pharma Competitors List
Related Companies and Tools
This page (NASDAQ:ERYP) was last updated on 1/23/2025 by MarketBeat.com Staff
Free ERYP Stock Alerts